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Abstract
Background—Higher Lp-PLA2 activity is associated with increased risk of coronary heart
disease (CHD), making Lp-PLA2 a potential therapeutic target. PLA2G7 variants associated with
Lp-PLA2 activity could evaluate whether this relationship is causal.
Methods and Results—A meta-analysis including a total of 12 studies (5 prospective, 4 case-
control, 1 case-only and 2 cross-sectional, n=26,118) was undertaken to examine the association
of: (i) LpPLA2 activity vs. cardiovascular biomarkers and risk factors and CHD events (two
prospective studies; n=4884); ii) PLA2G7 SNPs and Lp-PLA2 activity (3 prospective, 2 case-
control, 2 cross-sectional studies; up to n=6094); and iii) PLA2G7 SNPs and angiographic
coronary artery disease (2 case-control, 1 case-only study; n=4971 cases) and CHD events (5
prospective, 2 case-control studies; n=5523). Lp-PLA2 activity correlated with several CHD risk
markers. Hazard ratio for CHD events top vs. bottom quartile of Lp-PLA2 activity was 1.61
(95%CI: 1.31, 1.99) and 1.17 (95%CI: 0.91, 1.51) after adjustment for baseline traits. Of seven
SNPs, rs1051931 (A379V) showed the strongest association with Lp-PLA2 activity, VV subjects
having 7.2% higher activity than AAs. Genotype was not associated with risk markers,
angiographic coronary disease (OR 1.03 (95%CI 0.80, 1.32), or CHD events (OR 0.98 (95%CI
0.82, 1.17).
Conclusions—Unlike Lp-PLA2 activity, PLA2G7 variants associated with modest effects on
Lp-PLA2 activity were not associated with cardiovascular risk markers, coronary atheroma or
CHD. Larger association studies, identification of SNPs with larger effects, or randomised trials of
specific Lp-PLA2 inhibitors are needed to confirm/refute a contributory role for Lp-PLA2 in
CHD.
Keywords
genetics; epidemiology; risk factors; Mendelian randomization
Introduction
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is synthesised in macrophages and
activated platelets, transported in the circulation on HDL and LDL cholesterol particles, and
present in atheromatous plaques. Its effects could be proatherogenic, through the generation
of lysophosphatidylcholine and oxidized fatty acids, or antiatherogenic through the
hydrolysis of the pro-inflammatory mediator, platelet-activating factor and its analogues
formed upon oxidation of LDL [reviewed in1].
To date, more than 25 prospective cohort studies (both of general populations or individuals
with established coronary heart disease (CHD)) have reported a consistent association of
circulating Lp-PLA2 mass or activity with an increased risk of CHD. A literature-based
meta-analysis of 14 studies reported an odds ratio (OR) of 1.21 (95%CI: 1.11, 1.32) for a 1
standard deviation increase in the Lp-PLA2 mass and activity. 2 Lp-PLA2 is also associated
with other cardiovascular risk factors. For example, individuals with higher levels of Lp-
PLA2 tend to be older, to have higher levels of total-cholesterol, LDL cholesterol,
triglycerides, apolipoprotein (apo) B, higher blood pressure and body mass index, and lower
levels of HDL-cholestero.l3,4 However, it is uncertain whether one or more of these
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associated cardiovascular risk factors should be considered to be mediators or confounders
of the Lp-PLA2-CHD association.
Darapladib, the first specific inhibitor of Lp-PLA2 activity, reduced the volume of the
necrotic core of atheromatous plaque in a pig model 5 and in a randomised trial in humans
where intravascular coronary ultrasound was used to image coronary atheroma. 6 This effect
was achieved without an alteration in blood lipids. The effect of darapladib on
cardiovascular events is currently being addressed in the ongoing STABILITY trial
(NCT00799903), a phase-III outcome trial that will recruit up to 15,500 individuals.
In this study we investigated the relationship between common variants at PLA2G7
(encoding Lp-PLA2) with Lp-PLA2 activity, cardiovascular risk factors, angiographic CHD,
as well as coronary events in a large collaborative analysis of European populations,
exploiting the randomised allocation of alleles7 to better understand the nature of the
association between Lp-PLA2 and CHD.
Methods
Study populations
Twelve studies were included in the analysis (full details from each study are provided in
supplementary methods and supplementary Table 1). Ethical approval from relevant ethical
committees was obtained for all studies.
Prospective studies
Four of the 5 prospective cohort studies used population-based sampling, the Second
Northwick Park Heart Study (NPHS-II) 8, the European Prospective Investigation into
Cancer and Nutrition study, Norfolk-UK component (EPIC-Norfolk)9, the Edinburgh Artery
Study (EAS)10 and the Cyprus study,11 while the Whitehall-II Study (WH-II) was
workplace based12. In EPIC-Norfolk, the analysis was based on a nested subset of CHD
cases and controls matched for age, sex and study enrolment date.
Case-control studies
The Hypercoagulability and Impaired Fibrinolytic function MECHanisms predisposing to
MI (HIFMECH) study is a European multicentre case-control study of MI. A total of 527
cases (non-fatal events) and 566 controls were available for genotyping.13 AtheroGene 3 had
1318 individuals with coronary artery disease (CAD) defined as a diameter stenosis ≥ 30%
in at least one major coronary artery and a total of 485 healthy individuals. In the
Ludwigshafen Risk and Cardiovascular Health Study (LURIC) a CAD case was defined as
having ≥ 20% coronary stenosis in at least one of 15 coronary segments; a control was free
of angiographic evidence of coronary stenosis (731 controls and 2581 cases).14 Information
from the Wellcome Trust Case-Control study on CHD infarction (WTCCC-CHD) was
requested for SNPs in strong linkage disequilibrium with the SNP rs1051931. This study
contributed a total of 1988 CHD cases and 3004 controls.15
Case-only studies
For the Southampton Atherosclerosis Study (SAS) 1164 individuals with stenosis ≥ 50% in
at least one major epicardial coronary artery were included for genotyping. For SAS, the
NPHS-II prospective study was utilised as the control population for SNP-disease
associations. Both studies are UK based from similar geographical areas of recruitment.16
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Cross-sectional studies
The UCL DiAbetes and Cardiovascular Disease Study (UDACS) aimed to evaluate
cardiovascular risk factors for CHD in subjects with type 2 diabetes T2D. Here only
individuals of European descent (n=424) without CHD were included.17 For the
THROMBOgenic Factors and Recurrent Coronary Events Study (THROMBO)18 of MI
survivors, 529 individuals with DNA available were included in this analysis. Blood
markers (including Lp-PLA2 activity) included in the THROMBO study and presented here
were determined two months after the index MI. For the current analyses only the baseline
information was utilised, since coronary events were recurrent instead of incident events.
Data collection
Following a pre-determined analysis plan, information was obtained on Lp-PLA2 activity,
cardiovascular risk factors, PLA2G7 variants and cardiovascular events from 11
participating studies within the collaboration. Unified definitions of all relevant variables
utilised in the analysis were used. For a sub-set of pre-defined variables (Lp-PLA2 activity,
C-reactive protein, and triglycerides) natural-logarithmic transformations were used and
these variables were analysed in the log-scale. Covariates included in the different
multivariate models utilised to calculate risk of CHD were coded homogenously across all
the studies. We used study specific definitions for cardiovascular events (See supplementary
Table 1). Studies were then divided in two categories; those with CHD events as an outcome
(EPIC-Norfolk, NPHS-II, WH-II, EAS, Cyprus, HIFMECH and WTCCC-CHD) and those
with coronary artery disease defined by coronary angiography as an outcome (SAS,
AtheroGene and LURIC). All the analyses were limited to individuals of identified
European descent.
Laboratory analyses
Information on Lp-PLA2 activity was available from six of the studies. In order to reduce
inter-study variability, plasma Lp-PLA2 activity in AtheroGene, EPIC-Norfolk, NPHS-II,
UDACS and Cyprus, was determined in a single laboratory (Dr Ewa Ninio at INSERM
UMRS937, Paris) using a radiometric assay as reported previously.3,19 For these studies a
pool of plasma (always the same) was used to correct the data for inter-assay variability. For
the THROMBO study, plasma Lp-PLA2 activity was determined by a commercial
colorimetric assay (Cayman Chemical Co.) with 2-thio-PAF as substrate and according to
the manufacturer’s directions18. For the LURIC study, Lp-PLA2 activity was measured by
use of the Azwell Auto PAF-AH reagent set (Azwell). 20 The within-assay variability was
<10%.
Genotyping of single nucleotide polymorphisms in the PLA2G7 gene
Within the NPHS-II study, 12 tagging SNPs (tSNPs) were identified in PLA2G7 based on a
minor allele frequency (MAF) threshold >0.04 and r2 >80% (Supplementary Figure 1). In
addition to rs1051931 (which encodes A379V) the following SNPs: rs974670, , rs1421378,
rs1805017 (R92H) and rs9381475 were chosen for further investigation on the basis of
initial association of Lp-PLA2 activity in NPHS-II (Supplementary Table 2) and the recent
report by Sutton et al., which examined the association of PLA2G7 tSNPs and CHD risk.21
Genotype data on rs 1051931 was available for 11 studies. The SNPs rs974670, rs1421378,
rs1805017 and rs9381475 were previously genotyped in EPIC-Norfolk, EAS, Cyprus,
AtheroGene, UDACS and THROMBO. In addition, SNPs rs10948300 and rs2216465, were
already genotyped in UDACS and EPIC-NORFOLK. For the WTCCC-CHD we utilize the
SNP rs9472819 which is in complete LD (r2=1) with rs1051931. Details of the SNPs,
genotyping methods, and MAFs are summarised in Table 1.
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Statistical analyses
Association between Lp-PLA2 activity and CHD was assessed in the prospective NPHS-II
and EPIC-Norfolk studies and pooled using random effects models. Within each study a
hazard ratio (NPHS-II) and odds ratio (EPIC-Norfolk) and 95%CI for CHD by quartiles of
Lp-PLA2 activity was obtained, using the bottom quartile as the reference group.
Progressive adjustment for potential confounders was made in three separate models as
follows: model 1 included age (continuous) and sex, plus enrolment date in EPIC-Norfolk
and practice centre in NPHS-II. Model 2 included these variables together with BMI
(continuous), smoking (current-ex vs. never), diabetes (yes vs. no), systolic blood pressure
(continuous), fibrinogen (continuous), C-reactive protein (continuous log-transformed) and
alcohol (continuous as units/week) and model 3 included all preceding covariates with the
addition of total cholesterol (continuous), triglycerides (continuous log-transformed), Apo-B
(continuous) and Apo-AI (continuous). Since complete genotype and phenotype data was
not available for all 11 studies, the number included in the analysis of the relationship
between PLA2G7 genotype to Lp-PLA2 activity, PLA2G7 genotype and other intermediate
traits, and PLA2G7 genotype and CHD/angiographic CAD events differs. We detail for each
analysis, the number of studies and individuals included. The mean difference in log-Lp-
PLA2 activity for each PLA2G7 SNP was obtained from 7 studies (NPHS-II, EPIC-Norfolk,
Cyprus, UDACS, and THROMBO, and for AtheroGene and LURIC only the control group
was used in this analysis) including up to 6094 individuals. The effect on cardiovascular risk
factors of each PLA2G7 SNP was evaluated in all studies except SAS and WTCCC-CHD
(10 studies and 13,544 individuals).
The association between PLA2G7 SNPs and CHD events was assessed in 10 studies
(NPHS-II, EPIC-Norfolk, WH-II, HIFMECH, Edinburgh Artery, Cyprus, LURIC,
AtheroGene, SAS and WTCCC-CHD) a total of up to 10494 cases. The cross-sectional
studies, UDACs and THROMBO, were not included in this analysis. Within each study a
log-OR and standard error adjusted for age (continuous) and sex was obtained for each
genotype comparison: subjects heterozygous vs. individuals homozygous for the common-
allele (reference group), as well as those homozygous for rare-allele vs. those homozygous
for the common-allele. For WTCCC-CHD study, genotype counts were utilised to calculate
an unadjusted OR for the different genotype comparisons. For all previous analyses, results
across studies were pooled using random effects models. No imputations for missing
phenotype of genotype data was conducted. The outcome under evaluation (angiographic
CAD vs. CHD events), and study design (prospective vs. case-control), were evaluated as
potential sources of heterogeneity by meta-regression. With the combined dataset,
comprising 4971 cases of angiographic CAD, 5523 CHD events and 15,624 controls we had
95% power at p=0.001 to detect a per allele odds ratio of 1.2 (http://pngu.mgh.harvard.edu/
~purcell/gpc/). 22
Results
Lp-PLA2 activity, cardiovascular risk factors and risk of coronary heart disease
In two prospective studies (NPHS-II and EPIC-Norfolk) including 1030 cases and 3852
controls, BMI, blood pressure, total-cholesterol, LDL-cholesterol, Apo-B and triglycerides
were all higher by quartiles of increasing Lp-PLA2 activity. By contrast, Lp-PLA2 activity
was inversely correlated with HDL-cholesterol and Apo-AI. No clear associations were
observed with the emerging cardiovascular risk factors fibrinogen and C-reactive protein
(Figure 1).
Higher Lp-PLA2 activity was associated with a graded increase in risk of CHD with no
evidence of a threshold (Left panel, Figure 2). Individuals in the top quartile had a hazard
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ratio for CHD of 1.61 (95%CI: 1.31, 1.99) compared with individuals from the bottom
quartile in a model adjusted for age, sex, and enrolment date (Model-1). The magnitude of
the Lp-PLA2-CHD association slightly diminished with additional adjustment for BMI,
smoking, diabetes, systolic blood pressure, C-reactive protein, fibrinogen and alcohol
consumption (Model 2, HR of 1.56 (95%CI 1.24, 1.96) . When additional adjustment was
made for total-cholesterol, Apo-B, Apo-AI and triglycerides, (Model 3) the hazard ratio for
CHD fell further to 1.17 (95%CI: 0.91, 1.51) in individuals in the top quartile for Lp-PLA2
activity (Right panel, Figure 2).
PLA2G7 variants
Of the 4 SNPs where genotype data was available from the 12 studies ( Table 1), only on
four occasions was a borderline lack of Hardy Weinberg Equilibrium observed, with p=0.05
to 0.03. Since by chance alone we would expect 2 SNPs not to be in HWE, the borderline
deviation from Hardy Weinberg proportions are unlikely to affect the pooled analysis.
PLA2G7 variants and Lp-PLA2 activity
The following studies, NPHS-II, EPIC-Norfolk, Cyprus, UDACS, AtheroGene, LURIC and
THROMBO contributed information on one or more of seven PLA2G7 SNPs and Lp-PLA2
activity levels (expressed as a log-ratio) (Figure 3).
Using individuals homozygous for the common allele in each case as the reference group
(G1), we observed a statistically significant additive increase in Lp-PLA2 activity in
individuals carrying rs1051931 (A379V, n=5801). Compared to those homozygous for the
common allele (AA), individuals homozygous for the rare allele (VV) had a relative
difference in Lp-PLA2 activity of 7.2%, and heterozygous subjects (AV) had a 3% relative
difference. A trend was observed towards an inverse association with Lp-PLA2 activity for
the following gene-variants: rs1421378 (n=5141), rs1805017 (R92H; n=6094) and
rs2216465 (n=3471). None of these variants exhibited strong linkage disequilibrium (LD)
(r2 <0.2) with the rs1051931. A null association with the levels of Lp-PLA2 activity was
observed for the variants rs974670, rs9381475 and rs10948300 (Figure 3). For all previous
analyses, the exclusion of the THROMBO study did not modify the results (data available
on request).
PLA2G7 variants and cardiovascular risk factors
SNP rs1051931 with the largest effect on Lp-PLA2 activity was not associated with any of
the cardiovascular risk factors correlated with Lp-PLA2 activity itself, despite a large dataset
for BMI (n=4036), systolic blood pressure (n=4036), LDL-cholesterol (n=3292) and HDL-
cholesterol (n=3387) (Figure 4). We observed no effect of the rs1051931 variant on
additional cardiovascular risk factors such as diastolic blood pressure, glucose, and
homocysteine (data available on request).
PLA2G7 gene variants and risk of coronary heart disease
In pooled analysis of data from 10 studies (NPHS-II, EPIC-Norfolk, Cyprus, AtheroGene,
LURIC, THROMBO, WH-II, SAS, EAS and WTCCC-CHD) , with the total number of
combined outcomes ranging from 1627 to 10,494, there was no clear association of any of
the seven PLA2G7 variants with risk of CHD (Figure 5a), including rs1051931 (10,494
events) which was consistently associated with a modest difference in Lp-PLA2 activity (see
Figure 3). The null association of the rs1051931 variant was preserved where CHD events
and angiographically evaluated coronary artery disease were analysed separately. No
significant heterogeneity was observed according to the outcome evaluated (CHD event vs.
angiographic CAD) or according to study design (prospective vs. case-control). All P-
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values, derived from meta-regression, for the different genotype comparisons were > 0.1
(Figure 5b).
Discussion
In this analysis of pooled data from 12 studies with 26,118 participants we identified a clear
association of Lp-PLA2 activity with risk of CHD, but the effect size was sensitive to the
degree of adjustment for co-variables including blood lipids, with which Lp-PLA2 activity is
also associated. Several PLA2G7 variants that were associated with Lp-PLA2 activity, did
not exhibit any association with a wide range of established and novel cardiovascular risk
factors, suggesting that their association with CHD events or angiographic CHD should be
less prone to confounding. Despite some of the variants showing association with Lp-PLA2
activity, none showed a clear association with angiographic coronary disease or CHD
events. However, this null result needs to be interpreted in the light of the relatively weak
influence of these SNPs on Lp-PLA2 activity, the available sample size and therefore the
statistical power of the study.
The association of Lp-PLA2 activity with CHD risk was modified by the adjustment for
other cardiovascular risk factors in a multivariate analysis with the attenuation in effect size
being most marked when blood lipids were entered into the model. This involves a
judgement on which variables should be considered as potential mediators of the association
and which as confounders. Confounding factors should be balanced among groups of
individuals categorised by genotype for common SNPs in PLA2G7 that affect Lp-PLA2
activity, because genotype is determined by randomised allocation at conception. We
therefore identified variants in PLA2G7 associated with Lp-PLA2 activity and studied their
effect on other cardiovascular risk factors and CHD events. A careful selection of the
PLA2G7 SNPs was conducted to minimise the likelihood of a false-negative finding due to
inadequate selection of genetic tools. This included the identification of common tag-SNPs
for European-descent individuals which were initially evaluated in the NPHS-II study, and
whose results were then complemented with published-evidence on the effects of PLA2G7
variants on Lp-PLA2 activity and disease risk21, enabling a final selection of the seven
variants utilised in the genetic component of the analysis. Of the seven SNPs used, four
(rs1051931, rs1421378, rs1805017 and rs2216465) exhibited association with Lp-PLA2
activity (Figure 3), although the magnitude of these associations was small to moderate.
Indeed, rs1051931 which showed the strongest association, displayed only a relative
difference on Lp-PLA2 activity of 7.2% and 3% for rare allele homozygotes and
heterozygotes, respectively (see Figure 3); the other variants showed associations of similar
or lower magnitude.
Lp-PLA2 activity itself was correlated with a range of blood lipids in the current analysis,
and the findings are consistent with those of the Framingham Heart Study.23 However, we
found that rs1051931, which displayed the largest effect on Lp-PLA2 activity, showed no
association with blood lipids. This observation is consistent with data from the two short-
term randomised trials in humans using the Lp-PLA2 inhibitor, darapladib.6,24 Even though
Lp-PLA2 activity was reduced by about 60% (at a dose of 160 mg daily), darapladib did not
modify the concentrations of the lipid particles (LDL-, HDL-cholesterol or triglycerides).
These findings in combination suggest that blood lipids may be confounder rather than
mediators for the association between Lp-PLA2 activity and CHD risk.
In the current study, variants that affect Lp-PLA2 activity were not associated with coronary
atheroma detected by angiography. The absence of an effect on the degree of coronary
stenosis could be consistent with the experimental studies in a pig model of diabetic
hyperlipidaemia and a human trial of darapladib.5,6,24 In the pig study, 24 weeks treatment
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with darapladib led to only a modest reduction in coronary lesion size, but treated animals
showed a significant alteration in their plaque composition with a smaller necrotic core
populated by fewer inflammatory cells suggesting that darapladib treatment may reduce
plaque composition and vulnerability, independent of blood lipid changes. Similarly, in the
human studies of darapladib, there were detectable reductions in the area of necrotic core of
the athermatous plaques in coronary arteries in patients receiving the drug.24 The hypothesis
that this may translate to a reduction in plaque rupture and clinical events is now being
tested in the STABILITY trial.
There was no clear signal for an effect of PLA2G7 variants on CHD, despite the inclusion of
more than 10,494 cases (Figure 5a, b). However, given the small to modest effect of
common alleles at the PLA2G7 locus on Lp-PLA2 activity, and considering the strength of
the association of Lp-PLA2 activity and CHD risk (Figure 2), a per-allele OR as low as 1.05
(which we were insufficiently powered to detect) could still be compatible with a
contributory role of Lp-PLA2 to CHD. Other genetic studies examining this question have
yielded inconsistent findings.25,26 In a Taiwanese study of MIs before 45yrs, the rare allele
of rs1051931 was associated with increased risk of an event (OR= 1.66 [95%CI: 1.14.1,
5.80]), despite being associated with lower Lp-PLA2 activity, while the V279F variant
showed no association with enzyme activity or risk of MI.27 In a case-control study in
Chinese subjects of the seven SNPs in PLA2G7 studied singly or as haplotypes, only the
promoter SNP rs13210554 (not included in our analysis) was associated with increased
CHD risk, while the V279F variant and rs1805018 (but not rs1805017 or rs1051931)
showed association with lower Lp-PLA2 activity but were not associated with CHD risk.28
However, Sutton et al, reported a significant association of PLA2G7 variants, including
rs1805017 and rs1051931 with CHD risk in two multi-ethnic studies.21
Lp-PLA2 activity levels are stable among healthy subjects or patients with stable coronary
disease.29 It is important to consider whether other genetic variants might help delineate the
mechanisms underlying the association between Lp-PLA2 activity and CHD. Genetic
variants other than in PLA2G7 itself, in the genes MEF2A, CXCL12, VEGF, PTGIS and
CD44 (presumably acting in trans) may influence Lp-PLA2 activity23. We also previously
reported that variants in the APOE cluster explained ~4% of the variance in Lp-PLA2.30
However, variants in the vicinity of PLA2G7 itself (acting in cis) provide a much more
specific genetic tool than variants located outside this gene which could influence other
pathways. A number of approaches could be undertaken to overcome the problem that the
PLA2G7 SNPs studied so far are weak genetic instruments, which compromises statistical
power. These include expanding the dataset of European subjects included in a Mendelian
randomisation analysis; resequencing of the PLA2G7 gene in individuals of European
ancestry to identify less frequent variants with more extreme effects on Lp-PLA2 activity;
and undertaking more studies in subjects of Asian ancestry among whom there is a common
loss-of function variant (V279F) associated with a very substantial reduction in enzyme
activity with a frequency of heterozygotes of 25% and homozygotes of 1-4%.31,32 The
results from the association studies on this V279F variant have so far been inconclusive.
Earlier hospital based studies have indicated that subjects carrying the mutant allele are at
higher risk of arterial events (MI or stroke), as indicated in the study by Yamada et al.
including up to 850 cases and 1684 controls33. However, more recently a Korean case-
control study (532 cases: 670 controls) showed opposite results34 while the Chinese study of
827 cases and 947 controls did not find a significant association between the null variant and
CHD.28
In summary, in a tagging SNP approach using common PLA2G7 variants in a large scale
collaboration including approximately 26,000 European individuals, four SNPs were
identified with small to moderate association with Lp-PLA2 activity, but with no effect on
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lipid variables or CHD risk. However, the modest effect of these variants on Lp-PLA2
activity means that their expected effect on CHD risk, were Lp-PLA2 to be contributory,
would be predicted to be small, and even through the collaboration included over 10,400
cases, it may lack sufficient power to detect a genetic effect consistent with a causal role for
Lp-PLA2 in CHD. The STABILITY trial should inform on the efficacy and safety of
darapladib in particular and Lp-PLA2 inhibition in general for the prevention of CHD events
in a number of ethnic groups.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Lipoprotein-associated phospholipase A2 (Lp-PLA2) is transported in the circulation on
HDL and LDL cholesterol particles, and present in atheromatous plaques where it may
exert pro-atherogenic effects through generation of lysophosphatidylcholine and oxidized
fatty acids. Higher Lp-PLA2 activity is associated with increased risk of coronary heart
disease (CHD) in observational studies, making Lp-PLA2 a potential therapeutic target.
However, higher Lp-PLA2 activity may simply mark alterations in blood lipids and other
coronary heart disease (CHD) risk factors, reflect (rather than contribute to) plaque or
even play an anti-atherogenic role through the hydrolysis of the pro-inflammatory
mediator, platelet-activating factor and its analogues formed upon oxidation of LDL. We
identified common variants of the PLA2G7 gene that encodes Lp-PLA2 associated with
Lp-PLA2 activity and used these to clarify the nature of the association of Lp-PLA2 with
other putative risk factors and CHD events using Mendelian randomisation. Genetic
variants associated with modest effects on Lp-PLA2 activity were not associated with
major alterations in cardiovascular risk factors, coronary atheroma or CHD events.
Larger Mendelian randomisation analyses, perhaps using variants associated with larger
effects on Lp-PLA2 activity and randomised trials of specific Lp-PLA2 inhibitors, will
be needed to confirm/refute a contributory role for Lp-PLA2 in CHD.
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Figure 1.
Mean differences in cardiovascular traits by quartiles of Lp-PLA2 activity in NPHS-II and
EPIC-Norfolk. Subjects from the bottom quartile (Q1) were used as the reference group.
Footnote: This analysis are based on data from the control group of the EPIC-Norfolk study
(n = 1760) and the all participants from the prospective study NPHS-II (n= 2278) with the
relevant information.
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Figure 2.
Hazard ratio (HR) of coronary heart disease risk by quartiles of Lp-PLA2 activity in NPHS-
II and EPIC-Norfolk. Left panel describe the shape of the association using the minimally
adjusted model (model-1). Right panel describe the effect on the HR (top vs. bottom
quartile) of progressive levels of adjustment. Footnote: Hazard ratios for all the quartile with
the different level of adjustment are reported in supplementary Table-4.
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Figure 3.
Mean differences by genotype in the Lp-PLA2 activity levels according the PLA2G7
variants evaluated. Data pooled from up to 7 studies (NPHS-II, EPIC-Norfolk, Cyprus,
UDACS, AtheroGene, LURIC and THROMBO) including up to 6094 individuals.
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Figure 4.
Mean differences in cardiovascular risk factors by rs1051931 genotype according to the
PLA2G7 variants evaluated. Data pooled from up to 10 studies (all studies excluding SAS
and WTCCC-CHD) and 13,544 individuals. The X-axes from the previous plots are the
same as those in Figure 1, in order to increase visual comparability.
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Figure 5a.
Relative odds of CHD associated with PLA2G7 variants. Data pooled from up to 10 studies
(NPHS-II, EPIC-Norfolk, WH-II, HIFMECH, Edinburgh Artery, AtheroGene, LURIC,
Cyprus, SAS and WTCCC-CHD) including up to 10,494 CHD events.
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Figure 5b.
Effect of the rs1051931 variant on the risk of CHD stratified by outcome. CHD: Coronary
heart disease includes fatal and non-fatal events. Specific definitions used within each
studies are described in methods section. Angiographic-CAD: coronary artery disease
defined by coronary angiography, specific study definitions reported in methods section. *
P-values for heterogeneity between outcome (CHD vs. angiographic-CAD) were calculated
by meta-regression.
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